NU
Neurizon Therapeutics Limited
NUZ.AX · ASX
$0.08 +1.33% (+$0.00)
1M +25.00%
Market Cap $58.1M
P/E Ratio -
Div. Yield -
ROE 125.93%
Bulios Fair Price
$0.06
21.1% downside
Current Price
$0.076
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NUZ.AX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
43 /100
Fair P/B 4.57x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 48.46%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 68.44%
ROE 125.93%
ROA 45.25%
Debt
69 /100
Low Debt/Equity 0.26x
Current ratio 2.16x
Int. coverage -37.65x
Stability
32 /100
Unstable Beta 1.31x
EPS volatility 54.89%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NUZ.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ben Dingle
Employees
36
Headquarters
Melbourne